Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.63 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13365169 | 0.87 | OPRD1 (0.47) | OPRD1DRD3OPRM1OPRK1 | |
| Ketobemidone SCHEMBL29565806 | 0.84 | DRD3 (0.72) | OPRD1DRD3OPRM1OPRK1SLC22A1 | |
| Ketobemidone SCHEMBL24574 | 0.84 | DRD3 (0.72) | OPRD1DRD3OPRM1OPRK1SLC22A1 | |
| SCHEMBL12020311 | 0.84 | HDAC4 (0.49) | OPRD1DRD3OPRM1SLC22A1SLC6A4 | |
| SCHEMBL5753450 | 0.84 | OPRM1 (0.45) | OPRD1OPRM1OPRK1SLC22A1SLC6A4 | |
| Ketobemidone SCHEMBL9706814 | 0.83 | DRD3 (0.70) | OPRD1DRD3OPRM1OPRK1SLC22A1 | |
| SCHEMBL8324812 | 0.82 | OPRM1 (0.63) | OPRD1OPRM1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL15738407 | 0.82 | DRD3 (0.62) | OPRD1DRD3OPRM1OPRK1SLC22A1 | |
| Hydroxypethidine SCHEMBL29966554 | 0.81 | OPRM1 (0.74) | OPRD1OPRM1OPRK1SLC22A1SLC6A4 | |
| Hydroxypethidine SCHEMBL25246 | 0.81 | OPRM1 (0.74) | OPRD1OPRM1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423046-B1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS | G L PHARMA GMBH (AT) | 2020-08-12 | — | — | EP | claimed |
| EP-3560484-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2019-10-30 | — | — | EP | claimed |
| EP-3423034-B1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G L PHARMA GMBH (AT) | 2019-07-10 | — | — | EP | claimed |
| EP-3423046-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS | G.L. Pharma GmbH (AT) | 2019-01-09 | — | — | EP | claimed |
| EP-3423034-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2019-01-09 | — | — | EP | claimed |
| EP-3231420-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS | G.L. Pharma GmbH (AT) | 2017-10-18 | — | — | EP | claimed |
| EP-3210596-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2017-08-30 | — | — | EP | claimed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | TEIKOKU PHARMA USA, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250366978-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250251323-A1 | COLLECTION PROBE AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE | 2025-08-07 | — | — | US | disclosed |
| WO-2025128946-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20150216237-A1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | FONTEM HOLDINGS 1 B.V. (NL) | 2015-08-06 | — | — | US | disclosed |
| WO-2015112750-A1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | E-NICOTINE TECHNOLOGY, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| WO-2015054063-A1 | METHODS AND COMPOSITIONS FOR TREATING WITHDRAWAL SYNDROMES USING NON-SEDATIVE DEXMEDETOMIDINE TRANSDERMAL COMPOSITIONS | TEIKOKU PHARMA USA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150098983-A1 | Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions | TEIKOKU PHARMA USA, INC. | 2015-04-09 | — | — | US | disclosed |
| US-20140190496-A1 | METHODS AND DEVICES FOR COMPOUND DELIVERY | E-NICOTINE TECHNOLOGY, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014085719-A1 | METHODS AND DEVICES FOR COMPOUND DELIVERY | E-NICOTINE TECHNOLOGY, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20140144429-A1 | METHODS AND DEVICES FOR COMPOUND DELIVERY | E-NICOTINE TECHNOLOGY, INC. (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | OPRD1 4518/4885DRD3 4335/4885OPRM1 4810/4885 |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885DRD3 42/4885OPRM1 3/4885 |
| US-20150098983-A1 | Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions | CRH, OPRD1, ADRA2C | OPRD1 2/4885DRD3 58/4885OPRM1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.